Replimune Group (NASDAQ:REPL) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Replimune Group and Vir Biotechnology, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Replimune Group | 0 | 0 | 9 | 0 | 3.00 |
| Vir Biotechnology | 2 | 0 | 5 | 0 | 2.43 |
Replimune Group currently has a consensus target price of $56.00, suggesting a potential upside of 85.25%. Vir Biotechnology has a consensus target price of $66.00, suggesting a potential upside of 43.73%. Given Replimune Group's stronger consensus rating and higher probable upside, equities research analysts plainly believe Replimune Group is more favorable than Vir Biotechnology.
Valuation & Earnings
This table compares Replimune Group and Vir Biotechnology's revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Replimune Group | N/A | N/A | $-52,630,000.00 | ($1.54) | -19.63 |
| Vir Biotechnology | $8.09 million | 726.46 | $-174,680,000.00 | ($5.76) | -7.97 |
Replimune Group has higher earnings, but lower revenue than Vir Biotechnology. Replimune Group is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Replimune Group and Vir Biotechnology's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Replimune Group | N/A | -30.23% | -24.66% |
| Vir Biotechnology | -339.61% | -47.11% | -39.44% |
Risk & Volatility
Replimune Group has a beta of 2.63, suggesting that its share price is 163% more volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of -0.99, suggesting that its share price is 199% less volatile than the S&P 500.
Insider and Institutional Ownership
55.8% of Replimune Group shares are held by institutional investors. Comparatively, 54.5% of Vir Biotechnology shares are held by institutional investors. 50.9% of Replimune Group shares are held by insiders. Comparatively, 37.2% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Replimune Group beats Vir Biotechnology on 12 of the 13 factors compared between the two stocks.
